RSS | Login | Register

VIDEX EC

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare VIDEX EC to:

Generic Name for VIDEX EC

Didanosine 125mg, 200mg, 250mg, 400mg; e-c delayed-release caps.

Legal Classification:

Pharmacological Class for VIDEX EC

Nucleoside analogue (reverse transcriptase inhibitor).

Manufacturer of VIDEX EC

Bristol-Myers Squibb Virology

Indications for VIDEX EC

HIV-1 infection.

Adults and Children:

Take once daily on an empty stomach; swallow whole. <20kg: use oral soln. 20kg to <25kg: 200mg. 25kg to <60kg: 250mg. ≥60kg: 400mg. Renal impairment (CrCl 30–59mL/min): <60kg: 125mg. ≥60kg: 200mg. CrCl 10–29mL/min: 125mg. CrCl <10mL/min or dialysis: <60kg: use oral soln; ≥60kg: 125mg.

Also:

VIDEX PEDIATRIC PWD for ORAL SOLN

Precautions for VIDEX EC

Suspend if signs or symptoms of pancreatitis (discontinue if confirmed), lactic acidosis, or hepatotoxicity (eg, hepatomegaly or steatosis) occurs. Increased risk of pancreatitis (eg, alcohol abuse, advanced HIV disease, elderly, renal impairment); monitor. Women, obesity, or prolonged nucleoside exposure: increased risk of toxicity. Advanced HIV disease, history of neuropathy, or concomitant neurotoxic drugs: consider reducing dose or discontinuing if peripheral neuropathy occurs. Hepatic dysfunction. Hyperuricemia. Do periodic retinal exam. Elderly. Pregnancy (Cat.B); monitor for lactic acidosis if used with stavudine. Nursing mothers: not recommended.

Interactions for VIDEX EC

Extreme caution with pancreatotoxic drugs (eg, alcohol, stavudine, pentamidine): see literature. Caution with hydroxyurea, neurotoxic drugs (eg, stavudine). Potentiated by allopurinol (not recommended), ganciclovir, tenofovir (reduce dose of didanosine; monitor); increased didanosine toxicities with ribavirin (not recommended). Antagonized by methadone. For pediatric pwd: avoid magnesium- or aluminum-containing antacids. Separate dosing of delavirdine, indinavir, nelfinavir by 1 hour; give drugs affected by gastric pH (eg, ketoconazole, itraconazole) 2 hours prior. May antagonize quinolones, tetracyclines. Give at least 6 hours before or 2 hours after ciprofloxacin. See literature for dosing with concomitant tenofovir.

Adverse Reactions for VIDEX EC

GI disturbances, headache, rash; elevated liver enzymes, amylase, and lipase; pancreatitis, lactic acidosis/hepatomegaly with steatosis, retinal changes, optic neuritis, peripheral neuropathy, hyperuricemia, fat redistribution, immune reconstitution syndrome.

How is VIDEX EC supplied?

EC caps—30
Pediatric pwd (bottles)—1

Related Disease:

HIV~antivirals

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA update on H1N1 vaccine safety monitoring

January 19, 2010

The Commissioner of Food and Drugs has issued a letter to update healthcare professionals on the FDA/CDC experience with the H1N1 vaccination program and to provide some detail on the current vaccine safety monitoring program.